![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SH3TC1 |
Gene summary for SH3TC1 |
![]() |
Gene information | Species | Human | Gene symbol | SH3TC1 | Gene ID | 54436 |
Gene name | SH3 domain and tetratricopeptide repeats 1 | |
Gene Alias | SH3TC1 | |
Cytomap | 4p16.1 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | B3KWX8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54436 | SH3TC1 | HCC1_Meng | Human | Liver | HCC | 9.58e-28 | 1.05e-01 | 0.0246 |
54436 | SH3TC1 | HCC2_Meng | Human | Liver | HCC | 1.70e-02 | 4.55e-02 | 0.0107 |
54436 | SH3TC1 | HCC2 | Human | Liver | HCC | 3.06e-02 | 2.52e+00 | 0.5341 |
54436 | SH3TC1 | S014 | Human | Liver | HCC | 9.24e-04 | 2.46e-01 | 0.2254 |
54436 | SH3TC1 | S015 | Human | Liver | HCC | 8.85e-13 | 5.33e-01 | 0.2375 |
54436 | SH3TC1 | S016 | Human | Liver | HCC | 3.30e-11 | 3.83e-01 | 0.2243 |
54436 | SH3TC1 | S027 | Human | Liver | HCC | 2.09e-02 | 3.83e-01 | 0.2446 |
54436 | SH3TC1 | S028 | Human | Liver | HCC | 1.59e-11 | 4.64e-01 | 0.2503 |
54436 | SH3TC1 | S029 | Human | Liver | HCC | 5.16e-15 | 6.89e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SH3TC1 | SNV | Missense_Mutation | c.3885N>T | p.Glu1295Asp | p.E1295D | Q8TE82 | protein_coding | deleterious(0.03) | probably_damaging(0.98) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SH3TC1 | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | Q8TE82 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
SH3TC1 | SNV | Missense_Mutation | novel | c.98N>A | p.Arg33Gln | p.R33Q | Q8TE82 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SH3TC1 | SNV | Missense_Mutation | rs762197570 | c.464N>T | p.Ser155Phe | p.S155F | Q8TE82 | protein_coding | deleterious(0.02) | probably_damaging(0.991) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SH3TC1 | SNV | Missense_Mutation | rs200988451 | c.1124N>T | p.Ala375Val | p.A375V | Q8TE82 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SH3TC1 | SNV | Missense_Mutation | novel | c.1924N>A | p.Glu642Lys | p.E642K | Q8TE82 | protein_coding | deleterious(0.01) | benign(0.241) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
SH3TC1 | SNV | Missense_Mutation | novel | c.202C>T | p.Pro68Ser | p.P68S | Q8TE82 | protein_coding | tolerated(0.83) | benign(0.01) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SH3TC1 | SNV | Missense_Mutation | novel | c.643C>A | p.Leu215Met | p.L215M | Q8TE82 | protein_coding | tolerated(0.06) | benign(0.225) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SH3TC1 | SNV | Missense_Mutation | rs771254685 | c.2299C>T | p.His767Tyr | p.H767Y | Q8TE82 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SH3TC1 | SNV | Missense_Mutation | rs766520849 | c.727G>A | p.Ala243Thr | p.A243T | Q8TE82 | protein_coding | tolerated(0.4) | benign(0.138) | TCGA-AX-A3G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |